6th Annual Phase IV Clinical Trials
September 19 – 20, 2005 * Philadelphia, PA
Visit the conference website for more information and to register.
Phase IV studies have emerged as a powerful tool for companies to get their drugs to be used more broadly and for longer periods. The growth rate of Phase IV spending is continuing to increase. A Tufts Center for the Study of Drug Development analysis found that between 1998 and 2003, the U.S. FDA requested Post-Marketing commitments in 73% of the approvals for new drugs not previously approved in the U.S. Also, the FDA reported in March 2004 that there is 1,000 open commitment post-approval clinical and non-clinical toxicology studies. At this point less than 20% of post-approval studies are completed.
Attend CBI’s annual conference and gain insight from the regulatory, clinical, marketing, adverse events and Post-Marketing perspectives. The program provides a unique forum in which you can network with industry executives and Phase IV teams who can share their valuable experiences with you.
The 2005 program covers the latest issues on Phase IV studies including:
- Enforcement actions on regulations applicable to Phase IV
- The role of CMS and reimbursement on late stage development
- Operations of global Phase IV trials
- Trial design that meets both medical and marketing objectives
- And much more!
Hear what some of our previous attendees had to say:
“Competent speakers, delivering relevant commentary on real Phase IV issues – great event! See you next year!”
– Julie Bradshaw, Marketing Communications, AAI Development Services
“The speakers discussed topics of interest. Good opportunity to network with others in Phase IV studies”
— Janice McMannis, CRA, Roche Diagnostics
“Attending this program will elevate your understanding and appreciation for the value of Phase IV clinical trials” – Maureen Dowds, Medical Research Manager, Wyeth
“The Phase IV conference has been an excellent forum to highlight and reinforce the strategic importance and unique values of Phase IV studies in drug development and life cycle management.”
— Alexandre LeBeaut, Vice President, Medical Affairs, Novartis